Schiavetti Amalia, Pedetti Valeria, Varrasso Giulia, Marrucci Oriana, Celani Camilla, Andreoli Gianmarco, Bonci Enea
a Department of Pediatrics , Sapienza University , Rome , Italy.
b Department of Experimental Medicine , Sapienza University , Rome , Italy.
Pediatr Hematol Oncol. 2018 Apr;35(3):167-176. doi: 10.1080/08880018.2018.1476941. Epub 2018 Sep 19.
Little data is available on long-term renal impairment in survivors from childhood sarcoma. We investigated the prevalence of renal impairment and hypertension after very long-term follow-up in survivors who reached adulthood after treatment for childhood sarcoma.
A cross-sectional single center study was performed. Outcomes included estimating glomerular filtration rate (eGFR), albuminuria, glycosuria, serum phosphate and magnesium, tubular reabsorption phosphate (TRP), chronic kidney disease (CKD) according to the "Kidney Disease: Improving Global Outcomes" (KDIGO) guidelines and blood pressure (BP).
Out of 87 > 5-year sarcoma survivors, 30 adults (10F/20M, median age at diagnosis 9 years, median age at investigation 26 years, median follow-up 16 years, mean 19 years) were identified. Renal impairment was detected in four cases (13.3%); three of these fulfilled the criteria for CKD. Among the adult survivors, a subgroup of 15 cases (50%) had received ifosfamide without confounding factors such as a diagnosis of genito-urinary rhabdomyosarcoma or administration of other potentially nephrotoxic chemotherapy (platinum-based drugs or methotrexate); no renal dysfunction was detected in this subgroup. In the whole cohort of sarcoma survivors, hypertension was diagnosed in four cases (13.3%); BP was significantly correlated with body mass index [p .014].
In our series of adult survivors treated for a diagnosis of sarcoma in their childhood, the prevalence of CKD was 10%. We found survivors treated with ifosfamide as the only nephrotoxic agent did not present glomerular or tubular toxicity at long term follow-up, but further studies including a larger number of cases are required to confirm it.
关于儿童肉瘤幸存者长期肾功能损害的数据较少。我们调查了儿童肉瘤治疗后成年的幸存者在极长期随访后的肾功能损害和高血压患病率。
进行了一项横断面单中心研究。结局包括根据“改善全球肾脏病预后”(KDIGO)指南评估肾小球滤过率(eGFR)、蛋白尿、糖尿、血清磷酸盐和镁、肾小管磷酸盐重吸收(TRP)、慢性肾脏病(CKD)以及血压(BP)。
在87名5年以上的肉瘤幸存者中,确定了30名成年人(10名女性/20名男性,诊断时的中位年龄为9岁,调查时的中位年龄为26岁,中位随访时间为16年,平均19年)。4例(13.3%)检测到肾功能损害;其中3例符合CKD标准。在成年幸存者中,15例(50%)的亚组接受了异环磷酰胺治疗,且无诸如泌尿生殖系统横纹肌肉瘤诊断或其他潜在肾毒性化疗(铂类药物或甲氨蝶呤)等混杂因素;该亚组未检测到肾功能障碍。在整个肉瘤幸存者队列中,4例(13.3%)被诊断为高血压;血压与体重指数显著相关[p = 0.014]。
在我们这组童年时期被诊断为肉瘤并接受治疗的成年幸存者中,CKD的患病率为10%。我们发现,仅接受异环磷酰胺治疗的幸存者在长期随访中未出现肾小球或肾小管毒性,但需要包括更多病例的进一步研究来证实这一点。